ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack
← catalyst calendarNCT06118281 · readout in 117 d
Sponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →. With Duke Clinical Research Institute.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
10,000estimated
Sites
970
Countries
Argentina, Australia, Brazil +21
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-06-25 | actual | When the study began enrolling |
| Primary completion | 2026-12-14 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-12-14 | estimated | The whole study's end, after follow-up |
| First posted | 2023-11-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Cardiovascular Risk
- Acute Myocardial Infarction (AMI)
Interventions
- Drug: Ziltivekimab
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFTime to first occurrence of a 3-component major adverse cardiovascular event (MACE) endpoint comprising: Cardiovascular (CV) death, Non-fatal myocardial infarction (MI), Non-fatal stroke
measured From randomisation (month 0) to end-of-study (up to 25 months)
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed